



Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary

Alvar Agustí^{1,22}, Bartolome R. Celli ^{2,22}, Gerard J. Criner³, David Halpin⁴, Antonio Anzueto⁵, Peter Barnes⁶, Jean Bourbeau ⁷, MeiLan K. Han⁸, Fernando J. Martinez⁹, Maria Montes de Oca¹⁰, Kevin Mortimer ^{6,11,12}, Alberto Papi ¹³, Ian Pavord¹⁴, Nicolas Roche ¹⁵, Sundeep Salvi¹⁶, Don D. Sin¹⁷, Dave Singh¹⁸, Robert Stockley¹⁹, M. Victorina López Varela²⁰, Jadwiga A. Wedzicha⁶ and Claus F. Vogelmeier²¹

¹Univ. Barcelona, Hospital Clinic, IDIBAPS and CIBERES, Barcelona, Spain. ²Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. ³Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA. ⁴University of Exeter Medical School College of Medicine and Health University of Exeter, Exeter, UK. ⁵South Texas Veterans Health Care System, University of Texas, San Antonio, TX, USA. ⁶National Heart and Lung Institute, Imperial College London, London, UK. ⁷McGill University Health Centre, McGill University, Montreal, QC, Canada. ⁸University of Michigan, Ann Arbor, MI, USA. ⁹Weill Cornell Medical Center/New York-Presbyterian Hospital, New York, NY, USA. ¹⁰Hospital Universitario de Caracas Universidad Central de Venezuela Centro Médico de Caracas, Caracas, Venezuela. ¹¹Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK. ¹²School of Clinical Medicine, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa. ¹³University of Ferrara, Ferrara, Italy. ¹⁴Respiratory Medicine Unit and Oxford Respiratory NIHR Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford, UK. ¹⁵Pneumologie, Hôpital Cochin AP-HP, Centre, Université Paris, Paris, France. ¹⁶Pulmocare Research and Education (PURE) Foundation, Pune, India. ¹⁷St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada. ¹⁸University of Manchester, Manchester, UK. ¹⁹University Hospital, Birmingham, UK. ²⁰Universidad de la República, Hospital Maciel Montevideo, Montevideo, Uruguay. ²¹Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University, German Center for Lung Research (DZL), Marburg, Germany. ²²Co-first authors.

Corresponding author: Alvar Agustí (aagusti@clinic.cat)



Shareable abstract (@ERSpublications)

Executive summary of the Global Strategy for Prevention, Diagnosis and Management of COPD 2023: the latest evidence-based strategy document from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) <https://bit.ly/3KCaTGe>

Cite this article as: Agustí A, Celli BR, Criner GJ, *et al.* Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. *Eur Respir J* 2023; 61: 2300239 [DOI: 10.1183/13993003.00239-2023].

Copyright ©2023 the American Thoracic Society.

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0. For commercial usage and reprints, please e-mail Diane Gern (dgern@thoracic.org)

This article has an editorial commentary:
<https://doi.org/10.1183/13993003.00366-2023>

Received: 9 Feb 2023
Accepted: 10 Feb 2023



Introduction

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) has published the complete 2023 GOLD report, which can be freely downloaded from its webpage (www.goldcopd.org) together with a “pocket guide” and “teaching slide set” [1]. It contains important changes compared to earlier versions, and incorporates 387 new references [1]. Here, we present an executive summary of this GOLD 2023 report [1] that summarizes aspects that 1) are relevant from a clinician's perspective and 2) updates evidence published since the prior executive summary in 2017.

New definition of COPD

The definition of a disease should only include the characteristics that distinguish it from other diseases [2]. Accordingly, GOLD 2023 proposes a new definition of COPD that, at variance with previous documents [3], focuses exclusively on these characteristics, separately from its epidemiology, causes, risk factors and diagnostic criteria that are discussed on their own.

GOLD 2023 defines COPD as a *heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea, cough, expectoration and/or exacerbations) due to abnormalities of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive, airflow obstruction.*

Pathogenesis: causes and risk factors

COPD results from dynamic, cumulative and repeated gene (G)–environment (E) interactions over the lifetime (T) that damage the lungs and/or alter their normal development/aging processes (*GETomics*) [4].

Environmental risk factors

Cigarette smoking is a key environmental risk factor for COPD. Cigarette smokers have a higher prevalence of respiratory symptoms and lung function abnormalities, a greater annual rate of forced expiratory volume in 1 s (FEV₁) decline and a greater COPD mortality rate than nonsmokers [5], yet fewer than 50% of heavy smokers develop COPD [6]. Passive exposure to cigarette smoke, other types of tobacco smoke (e.g. pipe, cigar, water pipe) [7–9], and marijuana [10] are also risk factors for COPD [11]. Smoking during pregnancy poses a risk for the fetus, by altering lung growth and development *in utero*, and possibly priming the immune system for abnormal/enhanced responses in the future [4, 12].

In low- and middle-income countries (LMICs), *COPD in nonsmokers* may be responsible for up to 60–70% of cases [13]. Because the LMICs contribute to over 85% of all COPD cases, nonsmoking risk factors account for over 50% of the global burden of COPD [13]. Wood, animal dung, crop residues, and coal (i.e. *biomass*), typically burned in poorly functioning stoves, may lead to very high levels of household air pollution [14], which is associated with increased COPD risk, although the extent to which household air pollution *versus* other poverty-related exposures explain the association is unclear [15, 16]. Compared to COPD in smokers, COPD in nonsmokers is more common in females, of younger age, who exhibit similar (or milder) respiratory symptoms and quality of life impairment. They have similar spirometric indices but greater small airways obstruction, less emphysema and lesser rate of lung function decline. Finally they show lower neutrophil count, higher eosinophil numbers in the sputum [13] and a similar defect in macrophage phagocytosis of pathogenic bacteria [17]. Research is needed to understand how interventions aimed at decreasing household air pollution can reduce the risk of COPD as well as what is the most appropriate pharmacotherapy for this type of COPD [13].

Occupational exposures, including organic and inorganic dusts, chemical agents, and fumes, are an under-appreciated environmental risk factor for COPD [18, 19]. The US National Health and Nutrition Examination Survey III estimated the fraction of COPD attributable to workplace exposures was 19.2% overall, and 31.1% among never-smokers [20].

Air pollution, which typically consists of particulate matter (PM), ozone, oxides of nitrogen or sulfur, heavy metals, and other greenhouse gases, is a major worldwide cause of COPD, responsible for ~50% of the attributable risk for COPD in LMICs [1]. The risk of air pollution to individuals is dose-dependent with no apparent “safe” threshold. Even in countries with relatively low ambient air pollution levels, chronic exposure to PM <2.5 µm and nitrogen dioxides significantly impairs lung growth in children [21], accelerates lung function decline in adults and increases the risk for COPD, especially among those with additional risk factors [22]. Air pollution also increases the risk of COPD exacerbations, hospitalizations, and mortality [23].

Genetic risk factors

The most relevant genetic risk factor for COPD identified are mutations in *SERPINA1*, leading to *alpha-1 antitrypsin deficiency*, a major circulating inhibitor of serine proteases [24]. The *PiZZ* genotype affects 0.12% of COPD patients, and its prevalence ranges from 1/408 in Northern Europe to 1/1274 in Eastern Europe [25]. There is no increased COPD risk in heterozygotes (MZ and SZ) in the absence of smoking [26].

Other genetic variants have also been associated with reduced lung function and risk of COPD, their individual effect size is small although their co-occurrence may increase disease susceptibility [27].

Lung function trajectories: lung development and aging

At birth, the lungs are not fully developed. They grow and mature until about 20–25 years of age (earlier in females), when lung function reaches its peak [5]. This is followed by a relatively short *plateau* and a final phase of mild lung function decline due to physiological lung aging. This normal *lung function trajectory* can be altered by processes occurring during gestation, birth, childhood, and adolescence that affect lung growth (hence, peak lung function) and/or processes shortening the *plateau* phase and/or accelerating the aging phase [28]. Indeed, in the general population there is a range of lung function trajectories through the lifetime [28]. Trajectories below the normal range are associated with a higher prevalence and earlier incidence of multimorbidity and premature death [29], whereas those above the

normal range are associated with healthier aging, fewer cardiovascular and respiratory events, as well as with a survival benefit [30, 31].

Factors in early life termed “*childhood disadvantage factors*”, including prematurity, low birth weight, maternal smoking during pregnancy, repeated respiratory infections and poor nutrition, among others, are key determinants of peak lung function attained in early adulthood [32–39]. Reduced peak lung function in early adulthood increases the risk of COPD later in life [32, 40, 41]. In fact, approximately 50% of patients develop COPD due to accelerated decline in FEV₁ over time while the other 50% develop it due to abnormal lung growth and development (with normal lung function decline over time) [42].

Sex

The prevalence of COPD in developed countries is now almost equal in males and females [43]. Women report more dyspnea, worse health status scores and have a higher incidence of exacerbations compared with men at similar severity of airflow limitation [44].

Socioeconomic status

Poverty and lower socioeconomic status are consistently associated with airflow obstruction [45] and increased risk of COPD [46]. It is likely that this reflects exposures to household and outdoor air pollutants, crowding, poor nutrition, infections, or other factors related to low socioeconomic status.

Asthma

Many different studies have reported that asthma and atopy in infancy may be a significant risk factor for COPD in adulthood [47, 48]. However, it is important to remember that abnormal lung development in childhood and adolescence can cause asthma-like symptoms. Given that poor lung development is associated with COPD in adulthood (see above), some of these infants and adolescents may have been mislabeled as “asthma”.

Infections

Severe respiratory infections in childhood have been associated with reduced lung function and increased respiratory symptoms in adulthood [47, 49]. In adults, chronic bronchial infection, particularly with *Pseudomonas aeruginosa*, is associated with accelerated FEV₁ decline [50]. In many parts of the world, tuberculosis [51] and HIV infection [52] are also important risk factors for COPD.

Diagnosis: forced spirometry

A diagnosis of COPD should be *considered* in any patient who complains of dyspnea, chronic cough or sputum production, a history of recurrent lower respiratory tract infections and/or a history of exposure to risk factors for the disease (see above) but *forced vital capacity (FVC) maneuver during spirometry showing the presence of a post-bronchodilator FEV₁/FVC <0.7 is needed to establish the diagnosis of COPD*. The FEV₁ also serves to determine the *severity of airflow obstruction* (GOLD grades 1, 2, 3, and 4, or mild, moderate, severe, and very severe). Yet, several important aspects related to forced spirometry need to be considered here.

First, airflow obstruction that is not fully reversible is *not specific for COPD*. For instance, it may also be found in patients with asthma and other diseases, so the clinical context and risk factors (see above) must also be considered when establishing a diagnosis of COPD.

Second, if the post-bronchodilator FEV₁/FVC ratio is between 0.60 and 0.80 on a *single spirometric measurement*, this should be *confirmed by repeat spirometry* on a separate occasion, as in some cases the ratio may change as a result of biological variation when measured at a later interval [53, 54]. When the initial post-bronchodilator FEV₁/FVC ratio is <0.6, it is very unlikely to rise spontaneously above 0.7 [53].

Third, there is a long-standing debate on whether it is better to use a fixed FEV₁/FVC ratio <0.7 or the *lower limit of normal (LLN)* for the diagnosis of COPD. GOLD favors the use of the former because it is simple and independent of reference values, since it relates to variables measured in the same individual and has been used in all the clinical trials that form the evidence base on which treatment recommendations are drawn. GOLD 2023 acknowledges that use of a fixed FEV₁/FVC ratio <0.7 to define airflow obstruction may under-diagnose young adults and over-diagnose the elderly [55, 56], especially in mild disease, compared to using the LLN values of FEV₁/FVC. LLN values are based on the normal distribution and classify the bottom 5% of the healthy population as abnormal. Thus, LLN values are highly dependent on the choice of reference equations as well as race/ethnicity, and there are no longitudinal studies available validating the use of the LLN. Further, using the fixed ratio is not inferior to

LLN regarding prognosis [57]. Finally, the risk of misdiagnosis and over-treatment of individual patients using the fixed ratio as a diagnostic criterion is limited, as spirometry is only one biologic measurement to establish the clinical diagnosis of COPD in the appropriate clinical context (symptoms and risk factors). Diagnostic simplicity and consistency are crucial for the busy clinician.

Fourth, while *post-bronchodilator spirometry* is required for the diagnosis and assessment of COPD, assessing the degree of reversibility of airflow obstruction to inform therapeutic decisions is no longer recommended [58]. The degree of reversibility in a single patient varies over time and has not been shown to differentiate COPD from asthma (except when airflow limitation disappears following bronchodilators, which is incompatible with COPD), or to predict the response to long-term treatment with bronchodilators or corticosteroids [59]. Accordingly, it is not necessary nor advised [1] to stop inhaled medication before obtaining spirometry measurements during follow-up of patients.

Finally, the role of *screening spirometry* in the general population for the diagnosis of COPD is also controversial. In asymptomatic individuals without any significant exposure to tobacco or other risk factors, screening spirometry is probably not indicated. By contrast, in those with symptoms and/or risk factors (*e.g.* >20 pack-years of smoking, recurrent chest infections, prematurity or other significant early life events), the diagnostic yield for COPD is relatively high and spirometry should be considered as a method for *case finding* [1].

Terminology

As mentioned above, it is now well established that a range of lung function trajectories exist through life [28, 60] and that COPD can develop by both abnormal lung development and/or accelerated lung aging [42]. This has generated some terminological confusion, so GOLD proposes use of the following terminology [1]:

Early COPD

The word “early” means “near the beginning of a process”. Because COPD can start early in life and take a long time to manifest clinically, identifying “early” COPD is difficult. Further, a biological “early” related to the initial mechanisms that eventually lead to COPD should be differentiated from a clinical “early”, which reflects the initial perception of symptoms, functional limitation and/or structural abnormalities noted. Thus, GOLD proposes to use the term “early COPD” only to discuss the “biological” first steps of the disease in an experimental setting.

Mild COPD

Some studies have used “mild” airflow obstruction as a surrogate for “early” disease [61]. This assumption is incorrect because not all patients started their journey from a normal peak lung function in early adulthood, so some of them may never suffer “mild” disease in terms of “severity” of airflow obstruction [28]. Further, “mild” disease can occur at any age and may progress, or not, over time [60]. Accordingly, GOLD proposes that “mild” should be used only to describe the severity of airflow obstruction measured spirometrically.

Young COPD

The term “young COPD” is seemingly straightforward because it directly relates to the “chronological” age of the patient [62]. Given that lung function peaks at around 20 years [5] and starts to decline around 40–50 years, GOLD proposes to operationally consider “young COPD” in patients aged 20–50 years [63], whether from having never achieved normal peak lung function in early adulthood and/or from shorter plateau and/or early lung function decline [64, 65]. COPD in “young” people may be associated with significant structural and functional lung abnormalities with substantial impact on health [65, 66]. A family history of respiratory diseases and/or early-life events (including hospitalizations before the age of 5 years) is reported by a significant proportion of young patients with COPD [65].

Pre-COPD

This term has been proposed to identify individuals of any age, with respiratory symptoms and/or other detectable structural (*e.g.* emphysema) and/or functional abnormalities (*e.g.* hyperinflation, reduced lung diffusing capacity, or rapid FEV₁ decline), in the absence of airflow obstruction on post-bronchodilator spirometry (*i.e.*, FEV₁/FVC >0.7) [67]. These patients may (or not) develop persistent airflow obstruction (*i.e.* COPD) over time [67]. Yet, people with pre-COPD so defined should already be considered “patients” because they suffer symptoms and/or have functional and/or structural abnormalities. Currently, there is no evidence on what the best treatment is for these patients [68]. There urgently is a need for randomized

controlled trials, both in patients with “Pre-COPD”, and in young people with COPD [69]. Research in this area would benefit from pediatric-to-adulthood cohorts and more active case-finding strategies.

PRISm

This term has been proposed to describe individuals with FEV₁/FVC ≥0.7 and FEV₁ <80% of reference after bronchodilation [70, 71]. Its prevalence ranges from 7.1% to 20.3% [71], is particularly high in current and former smokers, and is associated with increased all-cause mortality [71]. PRISm can transition to normal, obstructive or restrictive spirometry over time [71]. Despite an increasing body of literature on PRISm, significant knowledge gaps remain in relation to its pathogenesis and treatment [71].

Taxonomy

Based on the different causes (or *etiotypes*) that can contribute to COPD (see above) GOLD 2023 proposes a new taxonomic classification of COPD (figure 1) that reflects two recent proposals [2, 72]. It aims to raise awareness about nonsmoking-related COPD and to stimulate research on the mechanisms and corresponding diagnostic, preventive or therapeutic approaches for these other etiotypes of COPD which are highly prevalent around the globe [13].

Clinical presentation

Patients with COPD may complain of dyspnea, wheezing, chest tightness, fatigue, activity limitation and/or cough with or without sputum production and may experience acute respiratory events characterized by acute worsening of respiratory symptoms called exacerbations that require specific preventive and therapeutic measures. Patients with COPD frequently harbor other comorbid diseases (multimorbidity) that influence their clinical condition and prognosis [73], independently of the severity of airflow obstruction due to COPD [73], and require specific treatment (see below).

Assessment

Once the diagnosis of COPD has been confirmed by spirometry, the goals of the initial assessment of COPD to guide therapy are to determine: 1) the severity of airflow limitation (GOLD spirometric grades); 2) the nature and magnitude of current symptoms; 3) the previous history of moderate and severe

Proposed taxonomy (etiotypes) for COPD	
Classification	Description
Genetically determined COPD (COPD-G)	Alpha-1 antitrypsin deficiency (AATD) Other genetic variants with smaller effects acting in combination
COPD due to abnormal lung development (COPD-D)	Early life events, including premature birth and low birthweight, among others
Environmental COPD	
Cigarette smoking COPD (COPD-C)	• Exposure to tobacco smoke, including <i>in utero</i> or <i>via</i> passive smoking • Vaping or e-cigarette use • Cannabis
Biomass and pollution exposure COPD (COPD-P)	Exposure to household pollution, ambient air pollution, wildfire smoke, occupational hazards
COPD due to infections (COPD-I)	Childhood infections, tuberculosis-associated COPD, HIV-associated COPD
COPD and asthma (COPD-A)	Particularly childhood asthma
COPD of unknown cause (COPD-U)	

Adapted from CELLI *et al.* [2] and STOLZ *et al.* [72].

FIGURE 1 Proposed taxonomy (etiotypes) for COPD. Reproduced with permission from www.goldcopd.org

exacerbations (the best estimate of the risk of future exacerbations); and 4) the presence and type of multimorbidity.

Combined initial COPD assessment: from ABCD to ABE

GOLD 2023 modifies the ABCD assessment tool of previous editions [74] to recognize the clinical impact of exacerbations independently of the level of symptoms of the patient [75] (figure 2). The thresholds proposed for symptoms (X axis) and history of exacerbations in the previous year (Y axis) are unchanged from previous GOLD documents, so the A and B groups remain unchanged, while the former C and D groups are now merged into a single group termed “E” (for “Exacerbations”). This has implications for the initial pharmacological treatment recommendations, as discussed below. The practical value of this proposal needs to be validated by appropriate clinical research.

Imaging

A chest X-ray cannot confirm a diagnosis of COPD. However, radiological changes associated with COPD may include signs of lung hyperinflation (flattened diaphragm and increased retrosternal air space), lung hyperlucency, and rapid tapering of the vascular markings. On the other hand, a chest X-ray can help exclude alternative diagnoses and establish the presence of significant comorbidities such as concomitant pulmonary fibrosis, bronchiectasis, pleural diseases, kyphoscoliosis, and cardiomegaly.

Computed tomography (CT) of the chest can provide information of potential clinical relevance, including: 1) presence, severity, and distribution of *emphysema*; this has implications for potential surgical or endoscopic lung volume reduction, is associated with faster FEV₁ decline, higher mortality and increased risk of lung cancer [76]; 2) about 30% of COPD patients have *bronchiectasis* visible on CT, which is associated with increased exacerbation frequency and mortality [77]; 3) most COPD patients fulfil the inclusion/exclusion criteria for *lung cancer screening* in the general population [78, 79], so they should be offered a similar strategy [1]; 4) quantification of *airway abnormalities*, although these methods are less well standardized than those used for emphysema quantification [80–82]; and, 5) a CT offers information about COPD *comorbidities* including coronary artery calcifications, pulmonary artery enlargement, bone




FIGURE 2 GOLD ABE assessment tool. Exacerbation history refers to exacerbations suffered the previous year. mMRC: modified Medical Research Council Dyspnea Questionnaire; CAT: COPD Assessment Test; FEV₁: forced expiratory volume in 1 s; FVC: forced vital capacity. Reproduced with permission from www.goldcopd.org

density and muscle mass, some of which are associated with all-cause mortality independently of the severity of airflow obstruction [83]. Thus, *GOLD 2023 recommends chest CT in COPD patients with persistent exacerbations, symptoms out of proportion to airflow limitation severity, severe airflow obstruction with significant hyperinflation and gas trapping, or for those who meet criteria for lung cancer screening.*

Pharmacological treatment

Pharmacological therapy must be always associated with non-pharmacological measures described later, starting with smoking cessation when needed.

Choice and appropriate use of inhaler devices

Because inhaled therapy is the cornerstone of COPD treatment, the appropriate use of these devices is crucial to optimize the benefit–risk ratio of any inhaled therapy. Achieving this goal requires educating and training the providers and the patients in the correct use of the device. Regular assessment at follow-up is necessary to maintain their effective use. Details on the choice of device can be found in the complete GOLD 2023 document and include availability, patient preferences and ability to perform the correct inhalation maneuver [84].

Initial pharmacological treatment

Figure 3 shows the 2023 GOLD recommendation for initiation of pharmacological therapy. The treatment of patients in Group A has not changed. In contrast, for patients in Group B, a dual long-acting bronchodilator combination (β_2 adrenergic (LABA) + anti-muscarinic (LAMA) bronchodilators) is now recommended since dual therapy is more effective than monotherapy with similar side-effects [85–87]. For patients in Group E, LAMA+LABA is also the recommended initial therapy, except for those patients with blood eosinophils ≥ 300 cells· μL^{-1} , in whom starting triple therapy (LABA+LAMA+inhaled corticosteroid (ICS)) can be considered. This is a practical recommendation; direct evidence is not available to guide therapy in naïve individuals. The role of the blood eosinophil count for the reduction of the exacerbation risk with ICS is explicitly discussed below. The use of LABA+ICS in COPD is no longer encouraged. If there is an indication for an ICS, then LABA+LAMA+ICS has been shown to be superior to LABA+ICS and is therefore the preferred choice [88, 89]. If patients with COPD have concomitant asthma, they should be treated as if they have asthma [90].




FIGURE 3 Initial pharmacological treatment. mMRC: modified Medical Research Council Dyspnea Questionnaire; CAT: COPD Assessment Test; LAMA: long-acting anti-muscarinic antagonist; LABA: long-acting β_2 receptor agonist; ICS: inhaled corticosteroid; eos: eosinophils. Reproduced with permission from www.goldcopd.org

Follow-up pharmacological treatment

Following initial therapy, patients should be reassessed guided by the principles of first *review* and *assess*, then *adjust* if needed.

GOLD 2023 continues to recommend that follow-up treatment be based on two key treatable traits (TTs) [91]: dyspnea and occurrence of exacerbations (figure 4). TTs can be identified based on clinical recognition (*phenotypes*) and/or on deep understanding of critical causal pathways (*endotypes*) through validated *biomarkers* (e.g. circulating eosinophils to guide treatment with ICS in COPD patients with evidence of T2 inflammation) [91]. Importantly, TTs can co-exist in the same patient [92] and change with time (spontaneously or because of treatment). GOLD 2023 recommendations for follow-up treatment for both TTs (dyspnea and exacerbations) broadly follow previous recommendations but no longer include LABA+ICS for the reasons stated above (see initial treatment).

For patients with persistent *dyspnea* or exercise limitation on bronchodilator monotherapy, a step up to LABA+LAMA is recommended. If this does not improve symptoms clinicians should consider switching inhaler device or molecules, as well as investigating and treating other causes of dyspnea.





FIGURE 4 Follow-up pharmacological treatment. LAMA: long-acting anti-muscarinic antagonist; LABA: long-acting β₂ receptor agonist; ICS: inhaled corticosteroid; eos: eosinophils; FEV₁: forced expiratory volume in 1 s. Reproduced with permission from www.goldcopd.org

For patients continuing to have *exacerbations* (with or without dyspnea) on bronchodilator monotherapy, escalation to LABA+LAMA is recommended, except for patients with blood eosinophils $\geq 300 \text{ cells}\cdot\mu\text{L}^{-1}$ who may be escalated to LABA+LAMA+ICS. For patients with persistent exacerbations on LABA+LAMA, escalation to LABA+LAMA+ICS is recommended if they have blood eosinophils $\geq 100 \text{ cells}\cdot\mu\text{L}^{-1}$. For patients continuing to exacerbate despite therapy with LABA+LAMA+ICS or those who have an eosinophil count of $<100 \text{ cells}\cdot\mu\text{L}^{-1}$, the addition of roflumilast (particularly in patients with chronic bronchitis and an $\text{FEV}_1 < 50\%$ predicted) [93–95] or a macrolide (particularly in patients who are not current smokers) may be considered [96, 97].

Patients whose pharmacological treatment is modified should be closely monitored. Treatment escalation has not been systematically tested and trials of de-escalation are limited to withdrawing ICS [98]. As indicated in figure 4, ICS de-escalation can be considered if pneumonia or other considerable side-effects occur. In case of blood eosinophils $\geq 300 \text{ cells}\cdot\mu\text{L}^{-1}$, ICS de-escalation is more likely to be associated with development of exacerbations. Finally, if a patient with COPD and no features of asthma has already been treated – for whatever reason – with LABA+ICS and is well controlled in terms of symptoms and exacerbations, then LABA+ICS could be continued. However, if they remain dyspneic switching to LABA+LAMA should be considered, and if they have further exacerbations, treatment should be escalated to LABA+LAMA+ICS.

Other therapeutic considerations
The eosinophil as a useful clinical biomarker

As in previous GOLD reports, the main factors to consider whether to initiate ICS treatment is based on a patient’s previous exacerbation history, and the blood eosinophil count (figure 5) [88, 89, 99–102]. Adding ICS has little or no effect at a blood eosinophil count $<100 \text{ cells}\cdot\mu\text{L}^{-1}$ whilst blood eosinophils $\geq 300 \text{ cells}\cdot\mu\text{L}^{-1}$ identify patients with a strong likelihood of treatment benefit [103, 104]. There is a continuous gradation of the preventive effect of ICS in patients with eosinophil values between 100 and 300 $\text{cells}\cdot\mu\text{L}^{-1}$, so some patients are likely to get benefit from adding ICS [103, 104]. Treatment decisions



can be based on historical eosinophil counts as the repeatability of blood eosinophil counts in a large primary care population appears reasonable [105], although greater variability is observed at higher thresholds [106].

Chronic bronchitis

Chronic bronchitis (CB) has been traditionally defined by “*cough and sputum production for at least 3 months per year for two consecutive years*” (in the absence of another cause that can explain this, a caveat that is often forgotten). The prevalence of CB in COPD patients ranges from 27% to 35%, being higher in males, younger age, greater pack-years of smoking, more severe airflow obstruction, rural location and increased occupational exposures. CB is associated with accelerated lung function decline, exacerbations, and mortality in COPD patients. Treatment of CB is unresolved but can include smoking cessation, long-acting muscarinic antagonists, oral mucolytics and antioxidants or oscillating positive expiratory pressure therapy; the use of inhaled mucolytics or recombinant human DNase have not shown promise [1]. Liquid nitrogen metered cryospray, rheoplasty, and targeted lung denervation are currently undergoing evaluation for CB treatment.

Affordability of inhaled medicines

In LMICs, there is limited availability and affordability of essential inhaled therapies for people with COPD, and this global inequity must be addressed urgently as part of efforts to achieve Universal Health Coverage and Sustainable Development Goal 3 [107]. On the other hand, even in developed countries, most inhaled medicines are still branded.

Reducing lung function decline and mortality in COPD

Pharmacotherapy has the potential to reduce the rate of lung function decline, but further studies are needed to know what patients can benefit most since not all patients exhibit accelerated lung function decline [1]. On the other hand, a number of pharmacological and non-pharmacological interventions (figure 6) reduce mortality in selected COPD patients. This emphasizes the need to implement targeted case-finding strategies, apply adequate patient characterization and provide appropriately individualized therapy.

Non-pharmacological therapy

Non-pharmacological treatment is a key part of the comprehensive management of COPD.

Education

All patients should receive basic information about COPD and its treatment (respiratory medications and inhalation devices), strategies to minimize dyspnea, and advice about when to seek help.

Smoking cessation

Approximately 40% of people with COPD continue to smoke despite knowing they have the disease, and this behavior has a negative impact on prognosis and progression of the disease [108]. All patients who continue to smoke should be offered help and treatment to quit.

Vaccination

Depending on local guidelines, patients should be offered vaccination against influenza, pneumococcus, coronavirus disease 2019 (COVID-19), pertussis, and herpes zoster, if they have not already received these [1].

Physical activity

Physical activity is decreased in COPD patients [109] so all COPD patients should be encouraged to keep active. The challenge is promoting and maintaining physical activity [110, 111]. Technology-based interventions have the potential to provide convenient and accessible means to enhance exercise self-efficacy, and to educate and motivate patients to make healthy lifestyle changes [112].

Pulmonary rehabilitation

Pulmonary rehabilitation (PR), including community- and home-based, is beneficial [1]. Accordingly, patients with high symptom burden and risk of exacerbations (GOLD groups B and E) should be recommended to take part in a *formal PR program* designed and delivered in a structured manner, considering the individual's COPD characteristics and comorbidities [113–116].

Tele-rehabilitation has been proposed as an alternative to the traditional approaches. This has become even more relevant in the COVID-19 pandemic era where in-person PR has not been feasible. However, it is important to distinguish between evidence-based tele-rehabilitation models and pandemic-adapted models. Multiple trials performed in groups and individuals with a large variety of tele-rehabilitation delivery

Evidence supporting a reduction in mortality with pharmacotherapy and non-pharmacotherapy in COPD patients

Therapy	RCT#	Treatment effect on mortality	Patient characteristics
Pharmacotherapy			
LABA+LAMA+ICS ¹	Yes	Single inhaler triple therapy compared to dual LABD therapy relative risk reduction: IMPACT: HR 0.72 (95% CI 0.53, 0.99) ^{1a} ETHOS: HR 0.51 (95% CI 0.33, 0.80) ^{1b}	Symptomatic people with a history of frequent and/or severe exacerbations
Non-pharmacological therapy			
Smoking cessation ²	Yes	HR for usual care group compared to intervention group (smoking cessation) HR 1.18 (95% CI 1.02, 1.37) ²	Asymptomatic or mildly symptomatic
Pulmonary rehabilitation ^{3¶}	Yes	Old trials: RR 0.28 (95% CI 0.10, 0.84) ^{3a} New trials: RR 0.68 (95% CI 0.28, 1.67) ^{3b}	Hospitalized for exacerbations of COPD (during or ≤4 weeks after discharge)
Long-term oxygen therapy ⁴	Yes	NOTT: ≥19 hours of continuous oxygen vs ≤13 hours: 50% reduction ^{4a} MRC: ≥15 hours vs no oxygen: 50% reduction ^{4b}	PaO ₂ ≤55 mmHg or <60 mmHg with <i>cor pulmonale</i> or secondary polycythemia
Noninvasive positive pressure ventilation ⁵	Yes	12% in NPPV (high IPAP level) and 33% in control HR 0.24 (95% CI 0.11, 0.49) ⁵	Stable COPD with marked hypercapnia
Lung volume reduction surgery ⁶	Yes	0.07 deaths per person-year (LVRS) vs 0.15 deaths per person-year (UC) RR for death 0.47 (p=0.005) ⁶	Upper lobe emphysema and low exercise capacity

#: RCT with pre-specified analysis of the mortality outcome (primary or secondary outcome); ¶: inconclusive results likely due to differences in pulmonary rehabilitation across a wide range of participants and settings.

1. a) IMPACT trial [192] and b) ETHOS trials [89]; 2. Lung Health Study [193]; 3. a) PUHAN *et al.* [156] and b) PUHAN *et al.* [157] and RYRSØ *et al.* [194]; 4. a) NOTT [195] and b) MRC [196]; 5. KOHLEIN *et al.* [197]; 6. NETT trial [198].

FIGURE 6 Evidence supporting a reduction in mortality with pharmacotherapy and non-pharmacotherapy in COPD patients. RCT: randomized controlled trial; ICS: inhaled corticosteroids; IPAP: inspiratory positive airway pressure; LABD: long-acting bronchodilator; LABA: long-acting β₂ agonist; LAMA: long-acting anti-muscarinic antagonist; P_{aO₂}: arterial partial pressure of oxygen; NPPV: noninvasive positive pressure ventilation; LVRS: lung volume reduction surgery; UC: usual treatment control group. Reproduced with permission from www.goldcopd.org

platforms (videoconferencing, telephone only, website with telephone support, mobile application with feedback, centralized “hub” for people to come together) suggest that tele-rehabilitation is safe and has similar benefits to those of center-based PR across a range of outcomes [117]. However, the optimal form of delivery, content and duration are not yet established [118, 119].

Oxygen therapy and ventilatory support

The criteria for prescribing long-term oxygen therapy and ventilator support remain unchanged and are described in detail in the GOLD 2023 report [1].

Surgical and endoscopic lung volume reduction

In selected patients with symptomatic heterogeneous or homogenous emphysema and significant hyperinflation refractory to optimized medical care, surgical or bronchoscopic modes of lung volume reduction may be considered (figure 7). In patients with a large *bullae*, surgical bullectomy is an option,




FIGURE 7 Surgical and interventional therapies in advanced emphysema. Homogeneous emphysema was defined as <10% difference in emphysematous destruction between the targeted and ipsilateral non-targeted lobe undergoing lung reduction as measured by quantitative chest computed tomography (CT) imaging. By contrast, >10% difference between the targeted and non-targeted lobe is considered a heterogeneous pattern of emphysematous destruction. CV: collateral ventilation measure by Chartis; FI+: fissure integrity >90% by high-resolution CT (HRCT); FI–: fissure integrity <90% by HRCT; ELVR: endoscopic lung volume reduction; EBV: endobronchial valve; VA: vapor ablation; LVRC: lung volume reduction coil; LVRS: lung volume reduction surgery. Reproduced with permission from www.goldcopd.org

and in selected patients with very severe COPD and without relevant contraindications, lung transplantation may be considered.

End of life and palliative care

All patients with advanced COPD should be considered for end of life and palliative care support to optimize symptom control and allow patients and their families to make informed choices about future management.

Exacerbations of COPD

A new definition

Exacerbations of COPD (ECOPD) negatively impact health status, disease progression and prognosis [120]. The previous GOLD definition of ECOPD was highly non-specific (“*acute worsening of respiratory symptoms that results in additional therapy*”) [3].

Besides, the severity of ECOPD was determined *post facto* (mild, moderate or severe) based on the use of healthcare resources [3], which is useless to guide treatment at the point of care.

To address these limitations, GOLD 2023 has adopted the recent consensus Rome proposal [120] which defines ECOPD as: “*an event characterized by dyspnea and/or cough and sputum that worsen over ≤14 days, which may be accompanied by tachypnea and/or tachycardia and is often associated with increased local and systemic inflammation caused by airway infection, pollution, or other insult to the airways*”.

Differential diagnosis

Patients with COPD are at increased risk of other acute events, particularly decompensated heart failure, pneumonia and/or pulmonary embolism that may mimic or aggravate an ECOPD (figure 8) [121]. Thus, while worsening of dyspnea, particularly if associated with cough and, purulent sputum, and no other symptoms or signs in a patient with COPD may be diagnosed as an ECOPD, other patients may have worsening of respiratory symptoms, particularly dyspnea without the classic characteristics of ECOPD, that should prompt careful consideration and/or search of those potential confounders, or contributors [121].




FIGURE 8 Classification of the severity of COPD exacerbations (ECOPD). VAS: visual analog scale; RR: respiratory rate; HR: heart rate; CRP: C-reactive protein. S_{aO_2} : arterial oxygen saturation; P_{aO_2} : arterial partial pressure of oxygen; P_{aCO_2} : arterial partial pressure of carbon dioxide; ABG: arterial blood gases. ABG should show new onset/worsening hypercapnia or acidosis since a few patients may have chronic hypercapnia. Reproduced with permission from www.goldcopd.org

Assessment of ECOPD severity

Based on a thorough review of the available literature and using a Delphi approach to agree on the variable thresholds, the Rome proposal suggests using easy to obtain clinical variables to define the severity of ECOPD (mild, moderate or severe) at the point of care (figure 8) [120]. In the primary care setting, severity can be determined with the easily obtainable dyspnea intensity (using a visual analog scale (VAS) 0 to 10 dyspnea scale with zero being not short of breath at all and 10 the worst shortness of breath you have ever experienced), respiratory rate, heart rate and oxygen saturation level. Where available, measuring blood C-reactive protein (CRP) levels is recommended (figure 8). To determine the need for ventilatory support (usually in the emergency room or hospital setting) arterial blood gases should be measured. To move from a mild to a moderate level, three of the variables need to exceed the established thresholds.

It is hoped that prospective validation will help better define exacerbations and their severity at point of contact, and that documented validation may confirm or help modify the proposed thresholds of the variables now included [122]. Likewise, it is proposed that prospective research can help determine a more specific marker of lung injury than the more generic CRP, as has been true for acute events of other organs (e.g. troponin level in patients with acute myocardial infarction).

Management of ECOPD

Treatment setting

Depending on the episode severity, as well as that of the underlying COPD and comorbidities, an ECOPD can be managed in either the outpatient or inpatient setting. The following are *indications for hospitalization*: 1) severe symptoms such as sudden worsening of resting dyspnea, high respiratory rate, decreased oxygen saturation, confusion, drowsiness; 2) acute respiratory failure; 3) onset of new physical signs (e.g. cyanosis, peripheral edema); 4) failure to respond to initial medical management; 5) presence of serious comorbidities (e.g. heart failure, newly occurring arrhythmias); and, 6) insufficient home support [1].

In the emergency department, hypoxemic patients should be provided with the appropriate concentration of supplemental oxygen and be assessed to determine if the increased work of breathing or impaired gas exchange require noninvasive ventilation. If so, healthcare providers should consider admission to an area where proper monitoring and care can be provided. In less severe cases, the patient may be managed in the emergency department or hospital ward unit.

Pharmacological treatment

Bronchodilators

Short-acting inhaled β_2 -agonists (SABA), with or without short-acting anticholinergics (SAMA), are the initial bronchodilators for acute treatment of ECOPD, administered using a metered-dose inhaler (MDI), with a spacer device if necessary, or nebulization [1]. If a nebulizer is chosen, air-driven is preferable to oxygen-driven nebulization to avoid the potential risk of increasing arterial partial pressure of carbon dioxide (P_{aCO_2}) [123]. The GOLD 2023 report recommends continuing treatments with long-acting bronchodilators during the exacerbation or to start these medications as soon as possible before hospital discharge [1]. Intravenous methylxanthines (theophylline or aminophylline) are not recommended due to lack of efficacy and significant side-effects [124, 125].

Glucocorticoids

Systemic glucocorticoids in COPD exacerbations improve lung function, oxygenation, risk of early relapse, and reduce treatment failures and length of hospitalization [126–128]. A dose of 40 mg prednisone-equivalent per day for 5 days is recommended [129]. Longer courses increase risk of pneumonia and mortality [130]. Therapy with oral prednisolone is equally effective to intravenous administration [131]. Nebulized budesonide may be a suitable alternative to systemic corticosteroids in some patients [127, 132]. Recent studies suggest that glucocorticoids may be less efficacious to treat COPD exacerbations in patients with lower blood eosinophil levels [133].

Antibiotics

Antibiotics should be given to patients with ECOPD who have increased sputum volume and sputum purulence and most of those requiring mechanical ventilation (invasive or noninvasive) [134]. The recommended length of antibiotic therapy is 5–7 days [135]. The choice of the antibiotic should be based on the local bacterial resistance pattern. Usually, initial empirical treatment is an aminopenicillin with clavulanic acid, macrolide, tetracycline or, in selected patients, quinolone. In patients with frequent exacerbations, severe airflow obstruction and/or exacerbations requiring mechanical ventilation, cultures from sputum or other materials from the lung should be performed, as Gram-negative bacteria (e.g. *Pseudomonas* spp.) or resistant pathogens that are not sensitive to the above-mentioned antibiotics may be

present. The route of administration (oral or intravenous) depends on the patient's ability to ingest medications and the pharmacokinetics of the antibiotic.

Adjunct therapies

Additional therapies may be indicated to maintain appropriate fluid balance, treat the comorbidities and monitor nutritional aspects. Hospitalized patients with COPD are at an increased risk of deep vein thrombosis and pulmonary embolism and prophylactic measures for thromboembolism should be instituted [136, 137]. At all times, healthcare providers should strongly enforce the need for smoking cessation.

Oxygen therapy

Supplemental oxygen for hypoxemia should be titrated to a target saturation of 88–92% [138]. In severe ECOPD, blood gases should be checked frequently or as clinically indicated to monitor for carbon dioxide retention and/or worsening acidosis. Pulse oximetry is not as accurate as arterial blood gas measurement [139] and, in particular, may overestimate blood oxygen content among individuals with darker skin tones [140]. Venturi masks offer more accurate and controlled delivery of inspired oxygen than do nasal prongs [1].

High-flow nasal therapy (HFNT) delivers heated and humidified air–oxygen blends *via* special devices at rates up to 8 L·min⁻¹ in infants and up to 60 L·min⁻¹ in adults [141]. HFNT has been associated with decreased respiratory rate and effort, improved lung mechanics and gas exchange, prolonged time to next exacerbation and improved health-related quality of life scores in COPD patients with acute (or chronic) hypercapnia [142–144], but did not prevent intubation in hospitalized patients with ECOPD [145]. In fact, the European Respiratory Society (ERS) recommends ventilatory support before using HFNT in hypercapnic ECOPD [146].

Ventilatory support

Ventilatory support can be provided by either noninvasive (NIV) means, with a nasal or facial mask, or invasive means, with an oro-tracheal tube or tracheostomy ventilation. NIV is the preferred initial mode of ventilation [147, 148]. It improves gas exchange and decreases respiratory rate, work of breathing, severity of breathlessness, intubation rates, complications (*e.g.* ventilator associated pneumonia), length of hospital stay and mortality [147, 148]. Once patients improve and can tolerate at least 4 h of unassisted breathing, NIV can be directly discontinued without any need for a “weaning” period [149].

Patients who fail NIV should receive invasive ventilation as subsequent rescue therapy [150]. The use of invasive ventilation in COPD is influenced by the likely reversibility of the precipitating event, the patient's wishes, and the availability of intensive care facilities [150]. When possible, advance directives or a “living will” makes these difficult decisions easier to resolve. Major hazards include the risk of ventilator-acquired pneumonia, barotrauma and volutrauma, and the risk of tracheostomy and consequential prolonged ventilation. Respiratory stimulants (*e.g.* caffeine, doxapram) are not recommended to treat ECOPD [1].

Hospital discharge, early readmissions, and follow-up

There are no standards to the timing and nature of hospital discharge but early readmissions during the first 90 days after discharge are frequent and constitute a significant healthcare problem. A systematic review has shown that comorbidities, previous exacerbations and hospitalization, and increased length of stay were significant risk factors for 30- and 90-day all-cause readmission after a hospitalized COPD exacerbation [151]. Hence, after an exacerbation it is good practice to cover education on correct use of the medications, provide support at home and a follow-up plan before discharge [152]. Early follow-up (within 1 month) should also be scheduled as it has been related to less exacerbation-related readmissions [153]. Additional follow-up at 3 months is recommended to ensure return to a stable clinical state and permit a review of the patient's symptoms, lung function, and where possible the assessment of prognosis using multiple scoring systems such as the BODE [154]. In addition, arterial oxygen saturation and arterial blood gas assessment will determine the need for long-term oxygen therapy more accurately [155]. The effects of initiation of pulmonary rehabilitation in the first 4 weeks after hospital discharge are unclear [156, 157].

Prognosis

Long-term prognosis following hospitalization for COPD exacerbation is poor, with a 5-year mortality rate of about 50% [158]. Factors independently associated with poor outcome include older age, lower body mass index, comorbidities (*e.g.* cardiovascular disease or lung cancer), previous hospitalizations for COPD exacerbations, clinical severity of the index exacerbation and need for long-term oxygen therapy at discharge [159–161].

Comorbidities, multimorbidity and frailty

COPD almost invariably coexists with other diseases (see below) that may significantly impact the patient's clinical condition and prognosis [162]. These comorbid conditions complicate the clinical picture because they can mimic the clinical presentation of COPD with similar complaints of dyspnea and chest tightness/pain and lead to misdiagnosis and missed opportunities for treatment. Additionally, comorbid conditions can further limit the pulmonary reserve of patients with COPD. Conversely, COPD may adversely affect the outcomes of many other disorders. For example, patients with heart failure or those undergoing coronary artery bypass grafting have greater morbidity and mortality when COPD is present compared to when it is absent. Some comorbidities arise independently of COPD, but others are causally related, either by shared risk factors or by one disease compounding the severity of the other [163].

In general, the presence of comorbidities should not alter COPD treatment and comorbidities should be treated per usual standards regardless of the presence of COPD. Attention should be directed to ensure simplicity of treatment and to minimize polypharmacy.

Cardiovascular diseases

Cardiovascular diseases are common in COPD, their prevalence ranging from 20 to 70% [164]. The types of cardiovascular comorbid conditions are diverse and span the spectrum from congestive heart failure to ischemic heart disease, arrhythmias, peripheral vascular disease and hypertension [164]. All these conditions should be treated in patients per established guidelines independent of the COPD diagnosis, including the use of selective β 1-blockers when a clear cardiovascular indication is present.

Lung cancer

Lung cancer occurs frequently in patients with COPD [165]. Like the general population, annual low-dose CT scan is recommended for lung cancer screening in COPD due to smoking [78, 79]. In patients with COPD not due to smoking, there is insufficient data to establish benefit over harm from lung cancer screening.

Bronchiectasis

Bronchiectasis affects approximately 30% of patients with COPD [166]. Increased sputum production, recurrent infections, and more frequent exacerbations hallmark bronchiectasis when it accompanies COPD. A chest CT scan is recommended if bronchiectasis is suspected.

Sleep apnea

Sleep apnea occurs in approximately 14% of COPD patients [167]. This worsens their prognosis since they have more frequent episodes of oxygen desaturation and a longer sleep time with hypoxemia and hypercapnia than obstructive sleep apnea patients without COPD.

Osteoporosis

Osteoporosis in COPD is often under-diagnosed and associated with poor health status and prognosis [168]. Recurrent use of systemic corticosteroids increases the risk of osteoporosis and should be avoided if possible.

Diabetes and metabolic syndrome

Studies show that diabetes is more frequent in COPD and the latter is likely to affect prognosis [164]. The prevalence of metabolic syndrome has been estimated to be more than 30% [169]. Diabetes and metabolic syndrome should be treated according to usual guidelines. COPD should be treated as usual.

Gastroesophageal reflux

Gastroesophageal reflux (GERD) is an independent risk factor for exacerbations and is associated with worse health status [170, 171]. The mechanisms responsible for increased risk of exacerbations are not yet fully established. Proton pump inhibitors are often used for treatment of GERD. One small, single-blind study suggested that these agents decrease the risk of exacerbation [172], but their value in preventing these events remains controversial, and the most effective treatment for this condition in COPD has yet to be established [173].

Anemia

Anemia is frequent in patients with COPD [174]. These patients are generally older, have more frequent cardiometabolic comorbidities, greater dyspnea, worse quality of life and airflow obstruction, reduced exercise capacity, and an increased risk of severe exacerbations with a higher mortality.

Secondary polycythemia

Secondary polycythemia may be associated with pulmonary hypertension [175, 176], venous thromboembolism [176], and mortality. Although the prevalence of polycythemia in COPD has decreased following the introduction of long-term oxygen therapy (LTOT) [177], one study reported its presence in 8.4% of patients with severe COPD receiving LTOT [178].

Mental health

Anxiety and depression are important and under-diagnosed comorbidities in COPD [179–182]. Both are associated with poor prognosis [181, 183], younger age, female sex, smoking, lower FEV₁, cough, higher St George's Respiratory Questionnaire (SGRQ) score, and a previous history of cardiovascular disease [179, 182, 184]. Cognitive impairment occurs in 32% of people with COPD, but neuropsychological testing suggests that up to 56% of them may suffer from it [185, 186].

Multimorbidity and frailty

An increasing number of aging patients suffer multimorbidity, defined as the presence of two or more chronic conditions. These patients have symptoms from multiple diseases making their presentation complex in the acute or chronic state. Multimorbidity results in frailty hallmarked by the presence of weakness, fatigue, exhaustion, low physical activity, and unintentional weight loss [187], a condition that has been reported to be more prevalent in patients with COPD.

COPD and COVID-19

Patients should follow basic infection control measures to help prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, including social distancing and washing hands, which are associated with reductions in the incidence of COVID-19 [188]. They should have COVID-19 vaccination in line with national guidelines. At times of high community incidence of COVID-19, patients should be advised to wear a facial covering [1] and should keep taking their oral and inhaled respiratory medications for COPD as directed, as there is no evidence that COPD medications should be changed during the COVID-19 pandemic [189].

Marked reductions in exacerbation rates and hospitalization for COPD have been reported during the initial phases of the pandemic [190], possibly because of infection control measures. Physical distancing and shielding, or sheltering-in-place, should not lead to social isolation and inactivity. Patients should stay in contact with their friends and families by telecommunication and continue to keep active. They should also ensure they have enough medication.

COPD patients are not at increased risk of infection with SARS-CoV-2, but this may reflect the effect of protective strategies [189, 191]. After accounting for potential confounding variables, COPD patients do have a higher risk of hospitalization, intensive care unit admission, and mortality [191]. COPD patients presenting with new or worsening respiratory or other symptoms that could be COVID-19 related, even if these are mild, should be tested for SARS-CoV-2.

New opportunities

COPD is a common, preventable, and treatable disease, but extensive under-diagnosis and misdiagnosis leads to patients receiving no treatment or incorrect treatment [1]. The realization that environmental factors other than tobacco smoking can contribute to COPD, that it can start early in life and affect young individuals, and that there are precursor conditions ("Pre-COPD", "PRISM"), opens new windows of opportunity for its prevention, early diagnosis, and prompt and appropriate therapeutic intervention [72]. Importantly, several pharmacological and non-pharmacological therapies have now been shown to reduce mortality of COPD patients (figure 6) but, in order to implement them, COPD must be diagnosed. Thus, any strategy aimed at addressing and improving the huge under-diagnosis of COPD in the community should be reinforced.

Acknowledgements: The authors acknowledge the support of Katie Langefeld and Ruth Hadfield for their careful editing of this 2023 GOLD report, as well as that of the members of the GOLD Emeriti Academy, GOLD Assembly and industry stakeholders for their comments and feedback.

Conflict of interest: A. Agustí is Chair of the Board of Directors of GOLD (no payment received), and reports grants or contracts from AZ, GSK, Chiesi and Menarini, consultancy fees from AZ, GSK, Chiesi, Menarini, Zambon, MSD and Sanofi, and payment or honoraria for lectures, presentations, manuscript writing or educational events from AZ, GSK, Chiesi, Menarini and Zambon, outside the submitted work. B.R. Celli reports support for the present work

from Chiesi Farmaceutici; grants or contracts from GlaxoSmithKline, AstraZeneca, Menarini, Sanofi Aventis and Axios, consultancy fees from GlaxoSmithKline, AstraZeneca and Sanofi Aventis, payment or honoraria for lectures, presentations, manuscript writing or educational events from GlaxoSmithKline, AstraZeneca, Menarini, Chiesi and Regeneron, support for attending meetings and/or travel from GlaxoSmithKline and Sanofi Aventis, and participation on a data safety monitoring board or advisory board for AZ Therapeutics, Sanofi Aventis and Vertex, outside the submitted work. G.J. Criner reports support for the present work from GlaxoSmithKline; grants or contracts from ALung Technologies Inc., American College of Radiology, American Lung Association, AstraZeneca, BioScale Inc., Boehringer Ingelheim, BREATH Therapeutics Inc., COPD Foundation, Coridea/ZIDAN, Corvus, Dr Karen Burns of St Michael's Hospital, Fisher & Paykel Healthcare Ltd, Galapagos NV, GlaxoSmithKline, Kinevent, Lungpacer Medical Inc., National Heart, Lung, and Blood Institute, Nurvaira Inc., Patient-Centered Outcomes Research Institute, Pulmonary Fibrosis Foundation, PulmonX, Respironics Inc., Respiant Sciences, Spiration Inc., Steward St Elizabeth's Medical Center of Boston Inc. and Veracyte Inc., and personal fees from Amgen, AstraZeneca, Boehringer Ingelheim, Broncus Medical, CSA Medical, EOLO Medical, Gala Therapeutics, GlaxoSmithKline, Helios Medical, Ion, Merck, Medtronic, Mereo BioPharma, NGM Biopharmaceuticals, Novartis, Olympus, PulmonX, Respironics Inc., Respiant Sciences, The Implementation Group and Verona Pharma, outside the submitted work. D. Halpin reports payment or honoraria for lectures, presentations, manuscript writing or educational events from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis, Pfizer, Sanofi and Menarini, support for attending meetings and/or travel from Menarini, and participation on a data safety monitoring board or advisory board with Chiesi, outside the submitted work. A. Anzueto reports consultancy fees from GlaxoSmithKline, AstraZeneca and Boehringer Ingelheim, and payment or honoraria for lectures, presentations, manuscript writing or educational events from Viatrix Pharma, outside the submitted work. P. Barnes reports grants or contracts from AstraZeneca and Boehringer Ingelheim, consultancy fees from AstraZeneca, Boehringer Ingelheim, Novartis, Teva and Epi-Endo, and payment or honoraria for lectures, presentations, manuscript writing or educational events from AstraZeneca, Boehringer Ingelheim, Novartis and Teva, outside the submitted work. J. Bourbeau reports grants or contracts from Canadian Institute of Health Research (CIHR), Réseau en santé respiratoire du FRQS, McGill University, McGill University Health Centre Foundation, AstraZeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd, Grifols, Novartis, Sanofi and Trudell Canada Ltd, and payment or honoraria for lectures, presentations, manuscript writing or educational events from AstraZeneca Canada Ltd, COVIS Pharma Canada Ltd, GlaxoSmithKline Canada Ltd, Pfizer Canada Ltd and Trudell Canada Ltd, outside the submitted work. M.K. Han reports grants or contracts from NIH, Sanofi, Novartis, Nuaira, Sunovion, Gala Therapeutics, COPD Foundation, AstraZeneca, American Lung Association, Boehringer Ingelheim and Biodesix, royalties or licences from Uptodate, Norton Publishing and Penguin Random House, consultancy fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pulmonx, Teva, Verona, Merck, Mylan, Sanofi, DevPro, Aerogen, Polarian, United Therapeutics, Regeneron, Altesa BioPharma and Amgen, payment or honoraria for lectures, presentations, manuscript writing or educational events from Cipla, Chiesi, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Medscape, Integrity and NACE, participation on a data safety monitoring board or advisory board with Novartis and Medtronic, leadership or fiduciary roles with COPD Foundation, COPD Foundation Scientific Advisory Committee, ALA advisory committee, American Thoracic Society (journal editor), ALA (volunteer spokesperson), GOLD scientific committee and Emerson School Board, stock or stock options with Meissa Vaccines and Altesa BioPharma, receipt of equipment, materials, drugs, medical writing, gifts or other services from GSK, Boehringer Ingelheim, AstraZeneca and Novartis, and personal fees from Medscape and Integrity, outside the submitted work. F.J. Martinez reports grants or contracts from AstraZeneca, Chiesi, GSK and Sanofi/Regeneron, consultancy fees from AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, GSK, Novartis, Polarean, Pulmonx, Sanofi/Regeneron, Sunovion, Teva, Theravance/Viatrix and UpToDate, payment or honoraria for lectures, presentations, manuscript writing or educational events from GSK and AstraZeneca, and participation on a data safety monitoring board or advisory board for MedTronic and GSK, outside the submitted work. M. Montes de Oca reports payment or honoraria for lectures, presentations, manuscript writing or educational events from GlaxoSmithKline and AstraZeneca, outside the submitted work. K. Mortimer has contributed to advisory boards for AstraZeneca and GlaxoSmithKline, outside the submitted work. A. Papi reports grants or contracts from Chiesi, AstraZeneca, GSK, Sanofi and Agenzia Italiana del Farmaco (AIFA), consultancy fees from Chiesi, AstraZeneca, GSK, Novartis, Sanofi, Avillion and Elpen Pharmaceuticals, payment or honoraria for lectures, presentations, manuscript writing or educational events from Chiesi, AstraZeneca, GSK, Menarini, Novartis, Zambon, Mundipharma, Sanofi, Edmond Pharma, Iqvia, Avillion and Elpen Pharmaceuticals, and participation on a data safety monitoring board or advisory board for Chiesi, AstraZeneca, GSK, MSD, Novartis, Sanofi, Iqvia, Avillion and Elpen Pharmaceuticals, outside the submitted work. I. Pavord reports speaker fees from Aerocrine AB, speaker and consultancy fees from Almirall and Novartis, speaker fees, payments for organization of educational events, consultancy fees and international scientific meeting sponsorship from AstraZeneca, GSK, Regeneron Pharmaceuticals, Inc., Sanofi and Teva, speaker fees, consultancy fees and international scientific meeting sponsorship from Boehringer Ingelheim, speaker fees, consultancy fees, research grants and international scientific meeting sponsorship from Chiesi, consultancy fees from Circassia, Dey Pharma, Genentech, Knopp Biosciences, Merck, MSD, RespiVert and Schering-Plough, and consultancy fees and international scientific meeting

sponsorship from Napp Pharmaceuticals, outside the submitted work. N. Roche reports grants or contracts from Boehringer Ingelheim, Novartis, GSK and Pfizer, consultancy fees from Boehringer Ingelheim, GSK, AstraZeneca, Sanofi, Chiesi, Pfizer, Novartis, Teva and Bayer, and payment or honoraria for lectures, presentations, manuscript writing or educational events from Boehringer Ingelheim, GSK, AstraZeneca, Sanofi, Chiesi, Pfizer, Novartis, Teva, Zambon and MSD, outside the submitted work. D.D. Sin reports payment or honoraria for lectures, presentations, manuscript writing or educational events from AstraZeneca, Boehringer Ingelheim and GSK, outside the submitted work. D. Singh reports consultancy fees from Aerogen, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, CSL Behring, Epiendo, Genentech, GlaxoSmithKline, Glenmark, Gossamerbio, Kinaset, Menarini, Novartis, Pulmatrix, Sanofi, Synairgen, Teva, Theravance and Verona, outside the submitted work. R. Stockley reports consultancy fees from CSL Behring and Mereo Biopharma, and participation on a data safety monitoring board or advisory board for Kamada and Syneos, outside the submitted work. J.A. Wedzicha reports grants or contracts from AstraZeneca, Boehringer, Chiesi, GSK, Novartis, Genentech and 37Clinical, consultancy fees from AstraZeneca, Epiendo, GSK, Gilead, Novartis, Pieris and Pulmatrix, payment or honoraria for lectures, presentations, manuscript writing or educational events from AstraZeneca, GSK, Boehringer, Recipharm and Novartis, and participation on a data safety monitoring board or advisory board for Virtus, outside the submitted work. C.F. Vogelmeier reports grants or contracts from German Ministry of Education and Science (BMBF), AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, GlaxoSmithKline, Grifols and Novartis, consultancy fees from Aerogen, AstraZeneca, Boehringer Ingelheim, CSL Behring, Chiesi, GlaxoSmithKline, Insmmed, Menarini, Novartis and Nuvaire, and payment or honoraria for lectures, presentations, manuscript writing or educational events from Aerogen, AstraZeneca, Boehringer Ingelheim, CSL Behring, Chiesi, GlaxoSmithKline, Insmmed, Menarini, Novartis, Roche and Sanofi, outside the submitted work. The remaining authors have no potential conflicts of interest to disclose.

References

- 1 Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Prevention, Diagnosis and Management of COPD: 2023 Report. <https://goldcopd.org/2023-gold-report-2/>
- 2 Celli B, Fabbri L, Criner G, *et al.* Definition and nomenclature of chronic obstructive pulmonary disease: time for its revision. *Am J Respir Crit Care Med* 2022; 206: 1317–1325.
- 3 Global Initiative for Chronic Obstructive Lung Disease. 2022 Global Strategy for Prevention, Diagnosis and Management of COPD. www.goldcopd.org
- 4 Agustí A, Melén E, DeMeo DL, *et al.* Pathogenesis of chronic obstructive pulmonary disease: understanding the contributions of gene–environment interactions across the lifespan. *Lancet Respir Med* 2022; 10: 512–524.
- 5 Kohansal R, Martinez-Camblor P, Agustí A, *et al.* The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. *Am J Respir Crit Care Med* 2009; 180: 3–10.
- 6 Rennard SI, Vestbo J. COPD: the dangerous underestimate of 15%. *Lancet* 2006; 367: 1216–1219.
- 7 Raad D, Gaddam S, Schunemann HJ, *et al.* Effects of water-pipe smoking on lung function: a systematic review and meta-analysis. *Chest* 2011; 139: 764–774.
- 8 Günen H, Tarraf H, Nemati A, *et al.* Waterpipe tobacco smoking. *Tuberk Toraks* 2016; 64: 94–96.
- 9 She J, Yang P, Wang Y, *et al.* Chinese water-pipe smoking and the risk of COPD. *Chest* 2014; 146: 924–931.
- 10 Tan WC, Lo C, Jong A, *et al.* Marijuana and chronic obstructive lung disease: a population-based study. *CMAJ* 2009; 180: 814–820.
- 11 Yin P, Jiang CQ, Cheng KK, *et al.* Passive smoking exposure and risk of COPD among adults in China: the Guangzhou Biobank Cohort Study. *Lancet* 2007; 370: 751–757.
- 12 Tager IB, Ngo L, Hanrahan JP. Maternal smoking during pregnancy. Effects on lung function during the first 18 months of life. *Am J Respir Crit Care Med* 1995; 152: 977–983.
- 13 Yang IA, Jenkins CR, Salvi SS. Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment. *Lancet Respir Med* 2022; 10: 497–511.
- 14 Orozco-Levi M, Garcia-Aymerich J, Villar J, *et al.* Wood smoke exposure and risk of chronic obstructive pulmonary disease. *Eur Respir J* 2006; 27: 542–546.
- 15 Mortimer K, Montes de Oca M, Salvi S, *et al.* Household air pollution and COPD: cause and effect or confounding by other aspects of poverty? *Int J Tuberc Lung Dis* 2022; 26: 206–216.
- 16 Sana A, Somda SMA, Meda N, *et al.* Chronic obstructive pulmonary disease associated with biomass fuel use in women: a systematic review and meta-analysis. *BMJ Open Respir Res* 2018; 5: e000246.
- 17 Ramírez-Venegas A, Montiel-Lopez F, Falfan-Valencia R, *et al.* The “slow horse racing effect” on lung function in adult life in chronic obstructive pulmonary disease associated to biomass exposure. *Front Med (Lausanne)* 2021; 8: 700836.
- 18 Paulin LM, Diette GB, Blanc PD, *et al.* Occupational exposures are associated with worse morbidity in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2015; 191: 557–565.
- 19 De Matteis S, Jarvis D, Darnton A, *et al.* The occupations at increased risk of COPD: analysis of lifetime job-histories in the population-based UK Biobank Cohort. *Eur Respir J* 2019; 54: 1900186.

- 20 Hnizdo E, Sullivan PA, Bang KM, *et al.* Association between chronic obstructive pulmonary disease and employment by industry and occupation in the US population: a study of data from the Third National Health and Nutrition Examination Survey. *Am J Epidemiol* 2002; 156: 738–746.
- 21 Guo C, Zhang Z, Lau AKH, *et al.* Effect of long-term exposure to fine particulate matter on lung function decline and risk of chronic obstructive pulmonary disease in Taiwan: a longitudinal, cohort study. *Lancet Planet Health* 2018; 2: e114–e125.
- 22 Bourbeau J, Doiron D, Biswas S, *et al.* Ambient air pollution and dysanapsis: associations with lung function and chronic obstructive pulmonary disease in the Canadian Cohort Obstructive Lung Disease Study. *Am J Respir Crit Care Med* 2022; 206: 44–55.
- 23 Li J, Sun S, Tang R, *et al.* Major air pollutants and risk of COPD exacerbations: a systematic review and meta-analysis. *Int J Chron Obstruct Pulmon Dis* 2016; 11: 3079–3091.
- 24 Stoller JK, Aboussouan LS. α 1-antitrypsin deficiency. *Lancet* 2005; 365: 2225–2236.
- 25 Blanco I, Diego I, Bueno P, *et al.* Prevalence of α (1)-antitrypsin PiZZ genotypes in patients with COPD in Europe: a systematic review. *Eur Respir Rev* 2020; 29: 200014.
- 26 Stockley RA. Alpha-1 antitrypsin deficiency: the learning goes on. *Am J Respir Crit Care Med* 2020; 202: 6–7.
- 27 Cho MH, Hobbs BD, Silverman EK. Genetics of chronic obstructive pulmonary disease: understanding the pathobiology and heterogeneity of a complex disorder. *Lancet Respir Med* 2022; 10: 485–496.
- 28 Agustí A, Faner R. Lung function trajectories in health and disease. *Lancet Respir Med* 2019; 7: 358–364.
- 29 Agustí A, Noell G, Brugada J, *et al.* Lung function in early adulthood and health in later life: a transgenerational cohort analysis. *Lancet Respir Med* 2017; 5: 935–945.
- 30 Çolak Y, Nordestgaard BG, Vestbo J, *et al.* Relationship between supernormal lung function and long-term risk of hospitalisations and mortality: a population-based cohort study. *Eur Respir J* 2021; 57: 2004055.
- 31 Çolak Y, Nordestgaard BG, Lange P, *et al.* Supernormal lung function and risk of COPD: a contemporary population-based cohort study. *EClinicalMedicine* 2021; 37: 100974.
- 32 Lawlor DA, Ebrahim S, Davey Smith G. Association of birth weight with adult lung function: findings from the British Women's Heart and Health Study and a meta-analysis. *Thorax* 2005; 60: 851–858.
- 33 Green M, Mead J, Turner JM. Variability of maximum expiratory flow-volume curves. *J Appl Physiol* 1974; 37: 67–74.
- 34 Ito K, Barnes PJ. COPD as a disease of accelerated lung aging. *Chest* 2009; 135: 173–180.
- 35 Martin TR, Feldman HA, Fredberg JJ, *et al.* Relationship between maximal expiratory flows and lung volumes in growing humans. *J Appl Physiol* (1985) 1988; 65: 822–828.
- 36 Rawlins EL, Okubo T, Xue Y, *et al.* The role of Scgb1a1+ Clara cells in the long-term maintenance and repair of lung airway, but not alveolar, epithelium. *Cell Stem Cell* 2009; 4: 525–534.
- 37 Smith BM, Kirby M, Hoffman EA, *et al.* Association of dysanapsis with chronic obstructive pulmonary disease among older adults. *JAMA* 2020; 323: 2268–2280.
- 38 Dharmage SC, Bui DS, Walters EH, *et al.* Lifetime spirometry patterns of obstruction and restriction, and their risk factors and outcomes: a prospective cohort study. *Lancet Respir Med* 2023; 11: 273–282.
- 39 Bose S, Pascoe C, McEvoy C. Lifetime lung function trajectories and COPD: when the train derails. *Lancet Respir Med* 2023; 11: 221–222.
- 40 Stern DA, Morgan WJ, Wright AL, *et al.* Poor airway function in early infancy and lung function by age 22 years: a non-selective longitudinal cohort study. *Lancet* 2007; 370: 758–764.
- 41 Regan EA, Lynch DA, Curran-Everett D, *et al.* Clinical and radiologic disease in smokers with normal spirometry. *JAMA Intern Med* 2015; 175: 1539–1549.
- 42 Lange P, Celli B, Agustí A, *et al.* Lung-function trajectories leading to chronic obstructive pulmonary disease. *N Engl J Med* 2015; 373: 111–122.
- 43 Landis SH, Muellerova H, Mannino DM, *et al.* Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012–2013. *Int J Chron Obstruct Pulmon Dis* 2014; 9: 597–611.
- 44 DeMeo DL, Ramagopalan S, Kavati A, *et al.* Women manifest more severe COPD symptoms across the life course. *Int J Chron Obstruct Pulmon Dis* 2018; 13: 3021–3029.
- 45 Townend J, Minelli C, Mortimer K, *et al.* The association between chronic airflow obstruction and poverty in 12 sites of the multinational BOLD study. *Eur Respir J* 2017; 49: 1601880.
- 46 Gershon AS, Warner L, Cascagnette P, *et al.* Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study. *Lancet* 2011; 378: 991–996.
- 47 de Marco R, Accordini S, Marcon A, *et al.* Risk factors for chronic obstructive pulmonary disease in a European cohort of young adults. *Am J Respir Crit Care Med* 2011; 183: 891–897.
- 48 McGeachie MJ, Yates KP, Zhou X, *et al.* Patterns of growth and decline in lung function in persistent childhood asthma. *N Engl J Med* 2016; 374: 1842–1852.
- 49 Allinson JP, Hardy R, Donaldson GC, *et al.* Combined impact of smoking and early life exposures on adult lung function trajectories. *Am J Respir Crit Care Med* 2017; 196: 1021–1030.

- 50 Martínez-García M, Faner R, Oscullo G, *et al.* Chronic bronchial infection is associated with more rapid lung function decline in chronic obstructive pulmonary disease. *Ann Am Thorac Soc* 2022; 19: 1842–1847.
- 51 Fan H, Wu F, Liu J, *et al.* Pulmonary tuberculosis as a risk factor for chronic obstructive pulmonary disease: a systematic review and meta-analysis. *Ann Transl Med* 2021; 9: 390.
- 52 Bigna JJ, Kenne AM, Asangbeh SL, *et al.* Prevalence of chronic obstructive pulmonary disease in the global population with HIV: a systematic review and meta-analysis. *Lancet Glob Health* 2018; 6: e193–e202.
- 53 Aaron SD, Tan WC, Bourbeau J, *et al.* Diagnostic instability and reversals of chronic obstructive pulmonary disease diagnosis in individuals with mild to moderate airflow obstruction. *Am J Respir Crit Care Med* 2017; 196: 306–314.
- 54 Schermer TR, Robberts B, Crockett AJ, *et al.* Should the diagnosis of COPD be based on a single spirometry test? *NPJ Prim Care Respir Med* 2016; 26: 16059.
- 55 van Dijk W, Tan W, Li P, *et al.* Clinical relevance of fixed ratio vs lower limit of normal of FEV₁/FVC in COPD: patient-reported outcomes from the CanCOLD cohort. *Ann Fam Med* 2015; 13: 41–48.
- 56 Guder G, Brenner S, Angermann CE, *et al.* GOLD or lower limit of normal definition? A comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study. *Respir Res* 2012; 13: 13.
- 57 Bhatt SP, Balte PP, Schwartz JE, *et al.* Discriminative accuracy of FEV₁:FVC thresholds for COPD-related hospitalization and mortality. *JAMA* 2019; 321: 2438–2447.
- 58 Albert P, Agusti A, Edwards L, *et al.* Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. *Thorax* 2012; 67: 701–708.
- 59 Hansen JE, Porszasz J. Counterpoint: Is an increase in FEV₁ and/or FVC $\geq 12\%$ of control and ≥ 200 mL the best way to assess positive bronchodilator response? No. *Chest* 2014; 146: 538–541.
- 60 Agusti A, Hogg JC. Update on the pathogenesis of chronic obstructive pulmonary disease. *N Engl J Med* 2019; 381: 1248–1256.
- 61 Zhou Y, Zhong NS, Li X, *et al.* Tiotropium in early-stage chronic obstructive pulmonary disease. *N Engl J Med* 2017; 377: 923–935.
- 62 Morla M, Busquets X, Pons J, *et al.* Telomere shortening in smokers with and without COPD. *Eur Respir J* 2006; 27: 525–528.
- 63 Martinez FJ, Han MK, Allinson JP, *et al.* At the root: defining and halting progression of early chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2018; 197: 1540–1551.
- 64 Colak Y, Afzal S, Nordestgaard BG, *et al.* Importance of early COPD in young adults for development of clinical COPD: findings from the Copenhagen General Population Study. *Am J Respir Crit Care Med* 2020; 203: 1245–1256.
- 65 Cosío BG, Pascual-Guardia S, Borrás-Santos A, *et al.* Phenotypic characterisation of early COPD: a prospective case-control study. *ERJ Open Res* 2020; 6: 00047–2020.
- 66 Sanchez-Salcedo P, Divo M, Casanova C, *et al.* Disease progression in young patients with COPD: rethinking the Fletcher and Peto model. *Eur Respir J* 2014; 44: 324–331.
- 67 Han MK, Agusti A, Celli BR, *et al.* From GOLD 0 to pre-COPD. *Am J Respir Crit Care Med* 2021; 203: 414–423.
- 68 Han MK, Ye W, Wang D, *et al.* Bronchodilators in tobacco-exposed persons with symptoms and preserved lung function. *N Engl J Med* 2022; 387: 1173–1184.
- 69 Martinez FA, Celli BR, Han, MK, *et al.* Treatment trials in Pre-COPD and young COPD: time to move forward. *Am J Respir Crit Care Med* 2022; 205: 275–287.
- 70 Wan ES, Castaldi PJ, Cho MH, *et al.* Epidemiology, genetics, and subtyping of preserved ratio impaired spirometry (PRISm) in COPDGene. *Respir Res* 2014; 15: 89.
- 71 Wan ES. The clinical spectrum of PRISm. *Am J Respir Crit Care Med* 2022; 206: 524–525.
- 72 Stolz D, Mkorombindo T, Schumann DM, *et al.* Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission. *Lancet* 2022; 400: 921–972.
- 73 Divo M, Cote C, de Torres JP, *et al.* Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2012; 186: 155–161.
- 74 Rodríguez-Roisin R, Rabe K, Vestbo J, *et al.* GOLD 20th anniversary: a brief history of time. *Eur Respir J* 2017; 50: 1700671.
- 75 Scioscia G, Blanco I, Arismendi E, *et al.* Different dyspnoea perception in COPD patients with frequent and infrequent exacerbations. *Thorax* 2017; 72: 117–121.
- 76 Haruna A, Muro S, Nakano Y, *et al.* CT scan findings of emphysema predict mortality in COPD. *Chest* 2010; 138: 635–640.
- 77 Martínez-García MA, de la Rosa-Carrillo D, Soler-Cataluna JJ, *et al.* Bronchial infection and temporal evolution of bronchiectasis in patients with chronic obstructive pulmonary disease. *Clin Infect Dis* 2021; 72: 403–410.
- 78 National Lung Screening Trial Research Team, Aberle DR, Adams AM, *et al.* Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med* 2011; 365: 395–409.

- 79 de Koning HJ, van der Aalst CM, de Jong PA, *et al.* Reduced lung-cancer mortality with volume CT screening in a randomized trial. *N Engl J Med* 2020; 382: 503–513.
- 80 Galban CJ, Han MK, Boes JL, *et al.* Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. *Nat Med* 2012; 18: 1711–1715.
- 81 Vasilescu DM, Martinez FJ, Marchetti N, *et al.* Noninvasive imaging biomarker identifies small airway damage in severe chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2019; 200: 575–581.
- 82 Bhatt SP, Soler X, Wang X, *et al.* Association between functional small airway disease and FEV1 decline in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2016; 194: 178–184.
- 83 Ezponda A, Casanova C, Divo M, *et al.* Chest CT-assessed comorbidities and all-cause mortality risk in COPD patients in the BODE cohort. *Respirology* 2022; 27: 286–293.
- 84 Halpin DMG, Mahler DA. A systematic review of published algorithms for selecting an inhaled delivery system in chronic obstructive pulmonary disease. *Ann Am Thorac Soc* 2022; 19: 1213–1220.
- 85 Mahler DA, Decramer M, D'Urzo A, *et al.* Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. *Eur Respir J* 2014; 43: 1599–1609.
- 86 Singh D, Ferguson GT, Bolitschek J, *et al.* Tiotropium+olodaterol shows clinically meaningful improvements in quality of life. *Respir Med* 2015; 109: 1312–1319.
- 87 Maltais F, Bjermer L, Kerwin EM, *et al.* Efficacy of umeclidinium/vilanterol *versus* umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. *Respir Res* 2019; 20: 238.
- 88 Lipson DA, Barnhart F, Brealey N, *et al.* Once-daily single-inhaler triple *versus* dual therapy in patients with COPD. *N Engl J Med* 2018; 378: 1671–1680.
- 89 Rabe KF, Martinez FJ, Ferguson GT, *et al.* Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. *N Engl J Med* 2020; 383: 35–48.
- 90 Reddel HK, Bacharier LB, Bateman ED, *et al.* Global initiative for asthma strategy 2021: executive summary and rationale for key changes. *Am J Respir Crit Care Med* 2022; 205: 17–35.
- 91 Agusti A, Bel E, Thomas M, *et al.* Treatable traits: toward precision medicine of airway diseases. *Eur Respir J* 2016; 47: 410–419.
- 92 Agusti A, Rapsomaniki E, Beasley R, *et al.* Treatable traits in the NOVELTY study. *Respirology* 2022; 27: 929–940.
- 93 Martinez FJ, Calverley PM, Goehring UM, *et al.* Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. *Lancet* 2015; 385: 857–866.
- 94 Martinez FJ, Rabe KF, Sethi S, *et al.* Effect of roflumilast and inhaled corticosteroid/long-acting β_2 -agonist on chronic obstructive pulmonary disease exacerbations (RE2SPOND). A randomized clinical trial. *Am J Respir Crit Care Med* 2016; 194: 559–567.
- 95 Rabe KF, Calverley PMA, Martinez FJ, *et al.* Effect of roflumilast in patients with severe COPD and a history of hospitalisation. *Eur Respir J* 2017; 50: 1700158.
- 96 Albert RK, Connett J, Bailey WC, *et al.* Azithromycin for prevention of exacerbations of COPD. *N Engl J Med* 2011; 365: 689–698.
- 97 Han MK, Tayob N, Murray S, *et al.* Predictors of COPD exacerbation reduction in response to daily azithromycin therapy. *Am J Respir Crit Care Med* 2014; 189: 1503–1508.
- 98 Magnussen H, Disse B, Rodriguez-Roisin R, *et al.* Withdrawal of inhaled glucocorticoids and exacerbations of COPD. *N Engl J Med* 2014; 371: 1285–1294.
- 99 Siddiqui SH, Guasconi A, Vestbo J, *et al.* Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2015; 192: 523–525.
- 100 Pascoe S, Locantore N, Dransfield MT, *et al.* Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. *Lancet Respir Med* 2015; 3: 435–442.
- 101 Papi A, Vestbo J, Fabbri L, *et al.* Extrafine inhaled triple therapy *versus* dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. *Lancet* 2017; 391: 1076–1084.
- 102 Vestbo J, Papi A, Corradi M, *et al.* Single inhaler extrafine triple therapy *versus* long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. *Lancet* 2017; 389: 1919–1929.
- 103 Agusti A, Fabbri LM, Singh D, *et al.* Inhaled corticosteroids in COPD: friend or foe? *Eur Respir J* 2018; 52: 1801219.
- 104 Singh D, Agusti A, Martinez FJ, *et al.* Blood eosinophils and chronic obstructive pulmonary disease: A Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 Review. *Am J Respir Crit Care Med* 2022; 206: 17–24.

- 105 Landis SH, Suruki R, Hilton E, *et al.* Stability of blood eosinophil count in patients with COPD in the UK Clinical Practice Research Datalink. *COPD* 2017; 14: 382–388.
- 106 Oshagbemi MOA, Burden DAM, Braeken MDCW, *et al.* Stability of blood eosinophils in COPD and controls and the impact of gender, age, smoking and baseline counts. *Am J Respir Crit Care Med* 2017; 195: 1402–1404.
- 107 Stolbrink M, Thomson H, Hadfield RM, *et al.* The availability, cost, and affordability of essential medicines for asthma and COPD in low-income and middle-income countries: a systematic review. *Lancet Glob Health* 2022; 10: e1423–e1442.
- 108 Montes de Oca M. Smoking cessation/vaccinations. *Clin Chest Med* 2020; 41: 495–512.
- 109 Pitta F, Troosters T, Spruit MA, *et al.* Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2005; 171: 972–977.
- 110 Mantoani LC, Rubio N, McKinstry B, *et al.* Interventions to modify physical activity in patients with COPD: a systematic review. *Eur Respir J* 2016; 48: 69–81.
- 111 Watz H, Pitta F, Rochester CL, *et al.* An official European Respiratory Society statement on physical activity in COPD. *Eur Respir J* 2014; 44: 1521–1537.
- 112 Spielmanns M, Gloeckl R, Jarosch I, *et al.* Using a smartphone application maintains physical activity following pulmonary rehabilitation in patients with COPD: a randomised controlled trial. *Thorax* 2022; in press [<https://doi.org/10.1136/thoraxjnl-2021-218338>].
- 113 Spruit MA, Singh SJ, Garvey C, *et al.* An Official American Thoracic Society/European Respiratory Society Statement: key concepts and advances in pulmonary rehabilitation. *Am J Respir Crit Care Med* 2013; 188: e13–e64.
- 114 Vogiatzis I, Rochester CL, Spruit MA, *et al.* Increasing implementation and delivery of pulmonary rehabilitation: key messages from the new ATS/ERS policy statement. *Eur Respir J* 2016; 47: 1336–1341.
- 115 Garvey C, Bayles MP, Hamm LF, *et al.* Pulmonary rehabilitation exercise prescription in chronic obstructive pulmonary disease: review of selected guidelines: an official statement from the American Association of Cardiovascular and Pulmonary Rehabilitation. *J Cardiopulm Rehabil Prev* 2016; 36: 75–83.
- 116 Stone PW, Hickman K, Steiner MC, *et al.* Predictors of referral to pulmonary rehabilitation from UK primary care. *Int J Chron Obstruct Pulmon Dis* 2020; 15: 2941–2952.
- 117 Cox NS, Dal Corso S, Hansen H, *et al.* Telerehabilitation for chronic respiratory disease. *Cochrane Database Syst Rev* 2021; 1: CD013040.
- 118 Houchen-Wolloff L, Steiner MC. Pulmonary rehabilitation at a time of social distancing: prime time for tele-rehabilitation? *Thorax* 2020; 75: 446–447.
- 119 Holland AE, Malaguti C, Hoffman M, *et al.* Home-based or remote exercise testing in chronic respiratory disease, during the COVID-19 pandemic and beyond: a rapid review. *Chron Respir Dis* 2020; 17: 1479973120952418.
- 120 Celli BR, Fabbri LM, Aaron SD, *et al.* An updated definition and severity classification of COPD exacerbations: the Rome proposal. *Am J Respir Crit Care Med* 2021; 204: 1251–1258.
- 121 Beghe B, Verduri A, Roca M, *et al.* Exacerbation of respiratory symptoms in COPD patients may not be exacerbations of COPD. *Eur Respir J* 2013; 41: 993–995.
- 122 Soler-Cataluña JJ, Miravittles M, Fernandez-Villar A, *et al.* Exacerbations in COPD: a personalised approach to care. *Lancet Respir Med* 2023; 11: 224–226.
- 123 Bardsley G, Pilcher J, McKinstry S, *et al.* Oxygen versus air-driven nebulisers for exacerbations of chronic obstructive pulmonary disease: a randomised controlled trial. *BMC Pulm Med* 2018; 18: 157.
- 124 Barr RG, Rowe BH, Camargo CA Jr. Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials. *BMJ* 2003; 327: 643.
- 125 Duffy N, Walker P, Diamantea F, *et al.* Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. *Thorax* 2005; 60: 713–717.
- 126 Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. *Lancet* 1999; 354: 456–460.
- 127 Maltais F, Ostinelli J, Bourbeau J, *et al.* Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. *Am J Respir Crit Care Med* 2002; 165: 698–703.
- 128 Aaron SD, Vandemheen KL, Hebert P, *et al.* Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. *N Engl J Med* 2003; 348: 2618.
- 129 Leuppi JD, Schuetz P, Bingisser R. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. *JAMA* 2013; 309: 2223–2231.
- 130 Sivapalan P, Ingebrigtsen TS, Rasmussen DB, *et al.* COPD exacerbations: the impact of long versus short courses of oral corticosteroids on mortality and pneumonia: nationwide data on 67 000 patients with COPD followed for 12 months. *BMJ Open Respir Res* 2019; 6: e000407.

- 131 de Jong YP, Uil SM, Grotjohan HP, *et al.* Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study. *Chest* 2007; 132: 1741–1747.
- 132 Gunen H, Hacievliyagil SS, Yetkin O, *et al.* The role of nebulised budesonide in the treatment of exacerbations of COPD. *Eur Respir J* 2007; 29: 660–667.
- 133 Bafadhel M, McKenna S, Terry S, *et al.* Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2012; 186: 48–55.
- 134 Anthonisen NR, Manfreda J, Warren CP, *et al.* Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. *Ann Intern Med* 1987; 106: 196–204.
- 135 Llor C, Moragas A, Miravittles M, *et al.* Are short courses of antibiotic therapy as effective as standard courses for COPD exacerbations? A systematic review and meta-analysis. *Pulm Pharmacol Ther* 2022; 72: 102111.
- 136 Couturaud F, Bertoletti L, Pastre J, *et al.* Prevalence of pulmonary embolism among patients with COPD hospitalized with acutely worsening respiratory symptoms. *JAMA* 2021; 325: 59–68.
- 137 Jimenez D, Agusti A, Tabernero E, *et al.* Effect of a pulmonary embolism diagnostic strategy on clinical outcomes in patients hospitalized for COPD exacerbation: a randomized clinical trial. *JAMA* 2021; 326: 1277–1285.
- 138 Austin MA, Wills KE, Blizzard L, *et al.* Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. *BMJ* 2010; 341: c5462.
- 139 Lacasse Y, Thériault S, St-Pierre B, *et al.* Oximetry neither to prescribe long-term oxygen therapy nor to screen for severe hypoxaemia. *ERJ Open Res* 2021; 7: 00272–2021.
- 140 Sjoding MW, Dickson RP, Iwashyna TJ, *et al.* Racial bias in pulse oximetry measurement. *N Engl J Med* 2020; 383: 2477–2478.
- 141 Roca O, Hernández G, Díaz-Lobato S, *et al.* Current evidence for the effectiveness of heated and humidified high flow nasal cannula supportive therapy in adult patients with respiratory failure. *Crit Care* 2016; 20: 109.
- 142 Fraser JF, Spooner AJ, Dunster KR, *et al.* Nasal high flow oxygen therapy in patients with COPD reduces respiratory rate and tissue carbon dioxide while increasing tidal and end-expiratory lung volumes: a randomised crossover trial. *Thorax* 2016; 71: 759–761.
- 143 Mauri T, Turrini C, Eronia N, *et al.* Physiologic effects of high-flow nasal cannula in acute hypoxemic respiratory failure. *Am J Respir Crit Care Med* 2017; 195: 1207–1215.
- 144 Nagata K, Horie T, Chohnabayashi N, *et al.* Home high-flow nasal cannula oxygen therapy for stable hypercapnic COPD: a randomized clinical trial. *Am J Respir Crit Care Med* 2022; 206: 1326–1335.
- 145 Xia J, Gu S, Lei W, *et al.* High-flow nasal cannula versus conventional oxygen therapy in acute COPD exacerbation with mild hypercapnia: a multicenter randomized controlled trial. *Crit Care* 2022; 26: 109.
- 146 Oczkowski S, Ergon B, Bos L, *et al.* ERS clinical practice guidelines: high-flow nasal cannula in acute respiratory failure. *Eur Respir J* 2022; 59: 2101574.
- 147 Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation – a consensus conference report. *Chest* 1999; 116: 521–534.
- 148 Osadnik CR, Tee VS, Carson-Chahhoud KV, *et al.* Non-invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2017; 7: CD004104.
- 149 Sellares J, Ferrer M, Anton A, *et al.* Discontinuing noninvasive ventilation in severe chronic obstructive pulmonary disease exacerbations: a randomised controlled trial. *Eur Respir J* 2017; 50: 1601448.
- 150 Chandra D, Stamm JA, Taylor B, *et al.* Outcomes of noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease in the United States, 1998–2008. *Am J Respir Crit Care Med* 2012; 185: 152–159.
- 151 Alqahtani JS, Njoku CM, Bereznicki B, *et al.* Risk factors for all-cause hospital readmission following exacerbation of COPD: a systematic review and meta-analysis. *Eur Respir Rev* 2020; 29: 190166.
- 152 Benzo R, Vickers K, Novotny PJ, *et al.* Health coaching and chronic obstructive pulmonary disease rehospitalization. A randomized study. *Am J Respir Crit Care Med* 2016; 194: 672–680.
- 153 Gavish R, Levy A, Dekel OK, *et al.* The association between hospital readmission and pulmonologist follow-up visits in patients with COPD. *Chest* 2015; 148: 375–381.
- 154 Oga T, Tsukino M, Haji T, *et al.* Predictive properties of different multidimensional staging systems in patients with chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis* 2011; 6: 521–526.
- 155 Spece LJ, Epler EM, Duan K, *et al.* Reassessment of home oxygen prescription after hospitalization for chronic obstructive pulmonary disease. a potential target for deimplementation. *Ann Am Thorac Soc* 2021; 18: 426–432.
- 156 Puhan MA, Gimeno-Santos E, Scharplatz M, *et al.* Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2011; 10: CD005305.
- 157 Puhan MA, Gimeno-Santos E, Cates CJ, *et al.* Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2016; 12: CD005305.

- 158 Hoogendoorn M, Hoogenveen RT, Rutten-van Mölken MP, *et al.* Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach. *Eur Respir J* 2011; 37: 508–515.
- 159 Guo Y, Zhang T, Wang Z, *et al.* Body mass index and mortality in chronic obstructive pulmonary disease: a dose-response meta-analysis. *Medicine (Baltimore)* 2016; 95: e4225.
- 160 Singanayagam A, Schembri S, Chalmers JD. Predictors of mortality in hospitalized adults with acute exacerbation of chronic obstructive pulmonary disease. *Ann Am Thorac Soc* 2013; 10: 81–89.
- 161 Piquet J, Chavaillon JM, David P, *et al.* High-risk patients following hospitalisation for an acute exacerbation of COPD. *Eur Respir J* 2013; 42: 946–955.
- 162 Beghe B, Clini E, Fabbri L. Chronic respiratory abnormalities in the multi-morbid frail elderly. *BRN Reviews* 2017; 3: 247–266.
- 163 Divo MJ, Casanova C, Marin JM, *et al.* COPD comorbidities network. *Eur Respir J* 2015; 46: 640–650.
- 164 Mannino DM, Thorn D, Swensen A, *et al.* Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. *Eur Respir J* 2008; 32: 962–969.
- 165 de Torres JP, Marin JM, Casanova C, *et al.* Lung cancer in patients with chronic obstructive pulmonary disease: incidence and predicting factors. *Am J Respir Crit Care Med* 2011; 184: 913–919.
- 166 Huang JT-J, Cant E, Keir HR, *et al.* Endotyping chronic obstructive pulmonary disease, bronchiectasis, and the “Chronic Obstructive Pulmonary Disease–Bronchiectasis Association”. *Am J Respir Crit Care Med* 2022; 206: 417–426.
- 167 Soler X, Gaio E, Powell FL, *et al.* High prevalence of obstructive sleep apnea in patients with moderate to severe chronic obstructive pulmonary disease. *Ann Am Thorac Soc* 2015; 12: 1219–1225.
- 168 Jorgensen NR, Schwarz P, Holme I, *et al.* The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a cross sectional study. *Respir Med* 2007; 101: 177–185.
- 169 Cebon Lipovec N, Beijers RJHCG, van den Borst B, *et al.* The prevalence of metabolic syndrome in chronic obstructive pulmonary disease: a systematic review. *COPD* 2016; 13: 399–406.
- 170 Hurst JR, Vestbo J, Anzueto A, *et al.* Susceptibility to exacerbation in chronic obstructive pulmonary disease. *N Engl J Med* 2010; 363: 1128–1138.
- 171 Ingebrigtsen TS, Marott JL, Vestbo J, *et al.* Gastro-esophageal reflux disease and exacerbations in chronic obstructive pulmonary disease. *Respirology* 2015; 20: 101–107.
- 172 Sasaki T, Nakayama K, Yasuda H, *et al.* A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients. *J Am Geriatr Soc* 2009; 57: 1453–1457.
- 173 Baumeler L, Papakonstantinou E, Milenkovic B, *et al.* Therapy with proton-pump inhibitors for gastroesophageal reflux disease does not reduce the risk for severe exacerbations in COPD. *Respirology* 2016; 21: 883–890.
- 174 Putcha N, Fawzy A, Paul GG, *et al.* Anemia and adverse outcomes in a chronic obstructive pulmonary disease population with a high burden of comorbidities. An analysis from SPIROMICS. *Ann Am Thorac Soc* 2018; 15: 710–717.
- 175 Nakamura A, Kasamatsu N, Hashizume I, *et al.* Effects of hemoglobin on pulmonary arterial pressure and pulmonary vascular resistance in patients with chronic emphysema. *Respiration* 2000; 67: 502–506.
- 176 Samareh Fekri M, Torabi M, Azizi Shoul S, *et al.* Prevalence and predictors associated with severe pulmonary hypertension in COPD. *Am J Emerg Med* 2018; 36: 277–280.
- 177 Kent BD, Mitchell PD, McNicholas WT. Hypoxemia in patients with COPD: cause, effects, and disease progression. *Int J Chron Obstruct Pulmon Dis* 2011; 6: 199–208.
- 178 Chambellan A, Chailleux E, Similowski T, *et al.* Prognostic value of the hematocrit in patients with severe COPD receiving long-term oxygen therapy. *Chest* 2005; 128: 1201–1208.
- 179 Hanania NA, Mullerova H, Locantore NW, *et al.* Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. *Am J Respir Crit Care Med* 2011; 183: 604–611.
- 180 Kunik ME, Roundy K, Veazey C, *et al.* Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. *Chest* 2005; 127: 1205–1211.
- 181 Ng TP, Niti M, Tan WC, *et al.* Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. *Arch Intern Med* 2007; 167: 60–67.
- 182 Maurer J, Rebbapragada V, Borson S, *et al.* Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. *Chest* 2008; 134: 43S–56S.
- 183 Eisner MD, Blanc PD, Yelin EH, *et al.* Influence of anxiety on health outcomes in COPD. *Thorax* 2010; 65: 229–234.
- 184 Chen W, Thomas J, Sadatsafavi M, *et al.* Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. *Lancet Respir Med* 2015; 3: 631–639.
- 185 Cleutjens FA, Franssen FM, Spruit MA, *et al.* Domain-specific cognitive impairment in patients with COPD and control subjects. *Int J Chron Obstruct Pulmon Dis* 2017; 12: 1–11.

- 186 Cleutjens F, Spruit MA, Ponds R, *et al.* Cognitive impairment and clinical characteristics in patients with chronic obstructive pulmonary disease. *Chron Respir Dis* 2018; 15: 91–102.
- 187 Fried LP, Tangen CM, Walston J, *et al.* Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci* 2001; 56: M146–M156.
- 188 Talic S, Shah S, Wild H, *et al.* Effectiveness of public health measures in reducing the incidence of Covid-19, SARS-CoV-2 transmission, and Covid-19 mortality: systematic review and meta-analysis. *BMJ* 2021; 375: e068302.
- 189 Halpin DMG, Criner GJ, Papi A, *et al.* Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med* 2021; 203: 24–36.
- 190 Alqahtani JS, Oyelade T, Aldhahir AM, *et al.* Reduction in hospitalised COPD exacerbations during COVID-19: a systematic review and meta-analysis. *PLoS ONE* 2021; 16: e0255659.
- 191 Halpin DMG, Rabe AP, Loke WJ, *et al.* Epidemiology, healthcare resource utilization, and mortality of asthma and COPD in COVID-19: a systematic literature review and meta-analyses. *J Asthma Allergy* 2022; 15: 811–825.
- 192 Lipson DA, Crim C, Criner GJ, *et al.* Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in COPD patients. *Am J Respir Crit Care Med* 2020; 201: 1508–1516.
- 193 Anthonisen NR, Skeans MA, Wise RA, *et al.* The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. *Ann Intern Med* 2005; 142: 233–239.
- 194 Rysø CK, Godtfredsen NS, Kofod LM, *et al.* Lower mortality after early supervised pulmonary rehabilitation following COPD-exacerbations: a systematic review and meta-analysis. *BMC Pulm Med* 2018; 18: 154.
- 195 Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. *Ann Intern Med* 1980; 93: 391–398.
- 196 Report of the Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. *Lancet* 1981; 1: 681–685.
- 197 Kohnlein T, Windisch W, Kohler D, *et al.* Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. *Lancet Respir Med* 2014; 2: 698–705.
- 198 Fishman A, Martinez F, Naunheim K, *et al.* A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. *N Engl J Med* 2003; 348: 2059–2073.